Ross Hannan

12PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Structural biology (incl. macromolecular modelling)Molecular targetsPredictive and prognostic markersPolymerisation mechanisms
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 27, 2024
CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci.

Donald P Cameron, Jirawas Sornkom, Sameerh Alsahafi

|May 09, 2024
Comprehensive translational profiling and STE AI uncover rapid control of protein biosynthesis during cell stress.

Attila Horvath, Yoshika Janapala, Katrina Woodward

|Aug 20, 2021
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.

Mitchell G Lawrence, Laura H Porter, Nicholas Choo

|Nov 11, 2020
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.

Shunfei Yan, Jiachen Xuan, Natalie Brajanovski

|Jul 12, 2020
Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.

Jixuan Gao, MoonSun Jung, Chelsea Mayoh

|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

Elaine Sanij, Katherine M Hannan, Jiachen Xuan

Pageof 2

Frequent Collaborators

7 joint publications

Richard B Pearson

4 joint publications

Katherine M Hannan

3 joint publications

Elaine Sanij

3 joint publications

Keefe T Chan